FUNDAMENTALS |
MarketCap: |
6 566.45 mill
|
EPS: |
-2.60
|
P/E: |
-66.29
|
Earnings Date: |
Nov 05, 2023 |
SharesOutstanding: |
38.10 mill
|
Avg Daily Volume: |
0.954 mill
|
RATING
2023-09-26 |
S-
|
Strong Buy
|
RATINGS |
Rating CashFlow: |
Neutral
|
|
Return On Equity: |
Strong Buy
|
|
Return On Asset: |
Strong Buy
|
|
DE: |
Strong Buy
|
|
P/E: |
Buy
|
|
Price To Book: |
Strong Buy
|
|
QUARTER GROWTHS |
|
1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE -66.29 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
-11.28x
|
Company: PE -66.29 | industry: PE 5.88
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 170.53 - 174.19
( +/- 1.06%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2023-09-26 | Desai Antal Rohit | Sell | 134 | Class A common stock |
2023-09-26 | Desai Antal Rohit | Sell | 993 929 | Class B common stock |
2023-09-26 | Mcgaughy R Kent Jr | Sell | 280 | Class A common stock |
2023-09-26 | Mcgaughy R Kent Jr | Sell | 278 309 | Class B common stock |
2023-09-26 | Mcgaughy R Kent Jr | Sell | 699 | Stock Option (right to buy) |
INSIDER POWER |
-100.00
|
Last
100 transactions |
Buy:
0 | Sell:
4 695 639 |
Forecast:
01:40 - $184.05
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$172.36 (0.02% )
|
Volume |
1.909 mill
|
Avg. Vol. |
0.954 mill
|
% of Avg. Vol |
200.11 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For RETA
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
Last 10 Buy Signals
Date |
Signal |
@ |
FITB | Apr 23 - 15:14 | $36.90 |
RTYUSD | Apr 23 - 15:04 | 2 018.40 |
VKTX | Apr 23 - 15:12 | $65.73 |
QRVO | Apr 23 - 15:12 | $108.31 |
INCY | Apr 23 - 15:10 | $51.90 |
DBX | Apr 23 - 15:10 | $23.47 |
^SP500-35 | Apr 23 - 15:10 | 1 643.97 |
YF-DAIUSD | Apr 23 - 15:08 | 45.41 |
LKQ | Apr 23 - 15:09 | $42.21 |
BIDU | Apr 23 - 15:09 | CNY98.34 |